Welcome to our dedicated page for CHIMERA INVESTMENT SEC filings (Ticker: CIMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHIMERA INVESTMENT's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHIMERA INVESTMENT's regulatory disclosures and financial reporting.
Vanguard Capital Management reports beneficial ownership of 4,187,562 shares of Chimera Investment Corp common stock, representing 5% of the class as of June 30, 2026. The firm holds sole voting power over 617,619 shares and sole dispositive power over all 4,187,562 shares, with no shared voting or dispositive power.
The position reflects securities beneficially owned or deemed beneficially owned by Vanguard Capital Management LLC and certain affiliated entities and business divisions, including various Vanguard asset management and advisory entities and Vanguard funds and managed accounts over which they exercise voting and/or dispositive power. Vanguard entities and managed accounts have rights to dividends and sale proceeds for these securities, but no other single person’s interest exceeds 5% of the class.
Mills Susan reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Susan Mills reported an award of 11,263 restricted stock units (RSUs) tied to Chimera common stock. Each RSU is economically equivalent to one share of common stock and is scheduled to vest on the earlier of June 11, 2027 or the next annual stockholders meeting. The award will be settled entirely in shares of Chimera common stock. Following this grant, Mills reports beneficial ownership of 37,757 shares, including the RSUs.
STILL DEBRA reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Debra Still received a grant of 11,263 restricted stock units (RSUs) of common stock as compensation. The award was recorded at a price of $0.00 per share, indicating a non-cash equity grant rather than an open-market purchase.
The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date on June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in shares of Chimera common stock. After this grant, Still directly holds 60,706 shares of Chimera common stock. Each RSU has the economic equivalent of one share of Chimera common stock.
Chavers Kevin Gerald reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Kevin Gerald Chavers reported an equity award of 11,263 restricted stock units (RSUs) tied to Chimera common stock. The RSUs, each economically equal to one share, were granted at no cash cost and will vest on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual stockholders meeting, then be settled entirely in shares. After this grant, Chavers holds 50,506 shares of Chimera common stock.
Walsh Cynthia B reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Cynthia B. Walsh received an equity award of 11,263 shares of common stock in the form of restricted stock units (RSUs). The grant was made at a stated price of $0.00 per share as a compensation award, not an open-market purchase.
The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date, June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in Chimera common stock on vesting. Following this grant, Walsh directly holds 26,765 shares of Chimera common stock, including the unvested RSUs. Each RSU has the economic equivalent of one share of Chimera common stock.
Reilly Brian Patrick reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Brian Patrick Reilly received an equity grant of 11,263 restricted stock units (RSUs) of common stock. The RSUs vest on the earlier of the first anniversary of the June 11, 2026 grant date or the next annual stockholders meeting and will be settled entirely in Chimera common shares. After this award, Reilly holds 106,133 shares of common stock, reflecting a compensation-related grant rather than an open-market purchase.
CREAGH GERARD reported acquisition or exercise transactions in this Form 4 filing.
Chimera Investment Corp director Gerard Creagh received an equity award of 11,263 restricted stock units (RSUs) on Chimera common stock. The RSUs are scheduled to vest on the earlier of the first anniversary of the grant date on June 11, 2027, or the date of Chimera’s next annual stockholders meeting, and will be settled entirely in shares of common stock. After this grant, Creagh directly holds 188,015 shares of Chimera common stock. This is a compensation-related grant rather than an open‑market purchase.
Chimera Investment Corporation held its 2026 annual stockholders meeting, where all management proposals passed with strong support. Holders of 63,285,465 of 83,645,571 common shares entitled to vote, or about 75.65%, were represented in person or by proxy.
Stockholders elected Class I directors Kevin G. Chavers, Gerard Creagh and Susan Mills to serve until the 2029 annual meeting. A non-binding advisory resolution approving the company’s executive compensation received 42,287,598 votes for versus 1,901,663 against. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Chimera Investment Corporation declared a second quarter 2026 cash dividend of $0.45 per common share. This matches its first quarter 2026 dividend and aligns with the Board’s previously stated expectation to maintain a $0.45 quarterly dividend throughout 2026, implying $1.80 per share on an annualized basis.
The dividend is payable on July 31, 2026 to common shareholders of record on June 30, 2026, with an ex-dividend date of June 30, 2026. The update was furnished under Regulation FD to keep investors informed about the company’s ongoing cash return policy.
Chimera Investment Corporation reported a net loss of $43.9 million for the quarter ended March 31, 2026, versus net income of $167.3 million a year earlier. Net interest income rose to $75.0 million, but large unrealized and realized losses on financial instruments and debt extinguishment pushed results negative.
Net income (loss) available to common shareholders was $(65.0) million, or $(0.78) per basic share, compared with $145.9 million or $1.79 per share in 2025. Total assets were $16.0 billion, stockholders’ equity was $2.46 billion, and common shares outstanding were 83.6 million as of April 30, 2026.